Coya Therapeutics (COYA) EBIT (2022 - 2026)

Coya Therapeutics has disclosed EBIT across 5 years of filings, most recently posting -$7.0 million for Q2 2026.

• In Q2 2026, EBIT fell 9.86% year-over-year to -$7.0 million; the TTM figure through Jun 2026 stood at -$23.2 million (down 2.34% YoY), while the FY2025 annual figure was -$22.6 million, down 30.76% from the prior year.
• EBIT came in at -$7.0 million for Q2 2026 at Coya Therapeutics, up from -$7.6 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $1.8 million in Q4 2023 to a low of -$7.7 million in Q1 2025.
• Average EBIT over 5 years is -$4.0 million, with a median of -$3.5 million recorded in 2022.
• Year-over-year, EBIT soared 190.6% in 2023 and plunged 324.79% in 2024.
• Over 5 years, EBIT stood at -$2.0 million in 2022, then soared by 190.6% to $1.8 million in 2023, then tumbled by 324.79% to -$4.1 million in 2024, then sank by 47.81% to -$6.0 million in 2025, then declined by 16.85% to -$7.0 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$7.0 million in Q2 2026, -$7.6 million in Q1 2026, and -$6.0 million in Q4 2025.